Evidence map›Paper›PMID 30021907›Full record

ArticleJournal of virology2018

Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection.

Binghao J Peng, Jonathan M Carlson, Michael K P Liu, Feng Gao, Nilu Goonetilleke, Andrew J McMichael, Persephone Borrow, Jill Gilmour, Sonya L Heath, Eric Hunter and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. HIV T-cell immunogen design and delivery.Current opinion in HIV and AIDS · 2022
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Binghao J PengDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jonathan M CarlsonMicrosoft Research, Redmond, Washington, USA.
Michael K P LiuNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Feng GaoDepartment of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.
Nilu GoonetillekeNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Andrew J McMichaelNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Persephone BorrowNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Jill GilmourIAVI Human Immunology Laboratory, Imperial College London, London, United Kingdom.
Sonya L HeathDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Eric HunterEmory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Anju BansalDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Paul A GoepfertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA pgoepfert@uabmc.edu.
University of Alabama at Birmingham · USUniversity of Oxford · GBDuke Medical Center · USEmory University · USImperial College London · GBMicrosoft (United States) · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
A-Z Clinical Trials UnitUM1AI069452 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 2012 to 2026
$28.8M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
HIV-1 Cryptic Epitopes: Implications for Vaccine DesignR01AI084772 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2009 to 2013
$2.5M
A Rational Approach for HIV Vaccine T Cell Epitope SelectionR01AI112566 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2014 to 2017
$1.9M
Analysis of Variant Epitope Specific CD8 T-Cells to Optimize HIV Vaccine DesignR56AI098551 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2012 to 2012
$636k
NCI NIH HHS P30 CA013148NIAID NIH HHS P30 AI027767NIAID NIH HHS R01 AI064060NIAID NIH HHS R01 AI084772NIAID NIH HHS R01 AI112566NIAID NIH HHS R56 AI098551NIAID NIH HHS UM1 AI069452NIAMS NIH HHS P30 AR048311
6 · The paper itself

Abstract

While prior studies have demonstrated that CD8 T cell responses to cryptic epitopes (CE) are readily detectable during HIV-1 infection, their ability to drive escape mutations following acute infection is unknown. We predicted 66 CE in a Zambian acute infection cohort based on escape mutations occurring within or near the putatively predicted HLA-I-restricted epitopes. The CE were evaluated for CD8 T cell responses for patients with chronic and acute HIV infections. Of the 66 predicted CE, 10 were recognized in 8/32 and 4/11 patients with chronic and acute infections, respectively. The immunogenic CE were all derived from a single antisense reading frame within

Indexed as

Immune EvasionAcute DiseaseAdultAmino Acid SequenceCD8-Positive T-LymphocytesChronic DiseaseCohort StudiesEpitopes, T-LymphocyteEvolution, MolecularFemaleGene Expression RegulationHIV-1HIV InfectionsHumansInterferon-gammaMaleEpitopes, T-LymphocyteInterferon-gammapol Gene Products, Human Immunodeficiency Virusacute infectionalternative reading framesCD8 T cellscryptic epitopeshuman immunodeficiency virusviral evolution

Identifiers

PMID30021907
PMCPMC6146806
OpenAlexW2884371059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.